BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-28 08:08 |
BerGenBio ASA: New share capital registered
|
English | 2.1 KB | ||
| 2024-05-23 15:15 |
BerGenBio ASA - Minutes from the annual general meeting 2024
|
Norwegian | 648.7 KB | ||
| 2024-05-23 15:15 |
BerGenBio ASA - Minutes from the annual general meeting 2024
|
English | 2.1 KB | ||
| 2024-05-22 05:00 |
BerGenBio ASA: Invitation to first quarter 2024 results webcast
|
English | 3.3 KB | ||
| 2024-04-30 12:00 |
BerGenBio ASA: Notice of Annual General Meeting
|
Norwegian | 437.7 KB | ||
| 2024-04-30 12:00 |
BerGenBio ASA: Notice of Annual General Meeting
|
English | 3.3 KB | ||
| 2024-04-30 11:00 |
BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REP…
|
English | 6.2 MB | ||
| 2024-04-30 11:00 |
BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REP…
|
English | 6.9 MB | ||
| 2024-04-30 11:00 |
BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REP…
|
English | 2.4 KB | ||
| 2024-04-25 10:55 |
BerGenBio ASA: New share capital registered
|
English | 2.4 KB | ||
| 2024-04-17 15:10 |
BerGenBio ASA: Resolution to increase the share capital for settlement of under…
|
English | 10.6 KB | ||
| 2024-04-17 07:42 |
BerGenBio - Disclosure of shareholding
|
English | 927 bytes | ||
| 2024-04-17 06:16 |
BerGenBio - Disclosure of large shareholding
|
English | 971 bytes | ||
| 2024-04-16 12:15 |
BerGenBio ASA: Final results for the last exercise period for warrants issued i…
|
English | 10.1 KB | ||
| 2024-04-15 08:58 |
BerGenBio ASA: Mandatory notification of trade by primary insiders and close as…
|
English | 131.4 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
